Cargando…

A Cohort Study to Evaluate the Risk of Hospitalisation for Congestive Heart Failure Associated with the Use of Aclidinium and Other Chronic Obstructive Pulmonary Disease Medications in the UK Clinical Practice Research Datalink

BACKGROUND: The long-acting anticholinergic (LAMA) aclidinium was approved in Europe in 2012 to relieve symptoms in adults with chronic obstructive pulmonary disease (COPD). A Post-Authorisation Safety Study (PASS) was initiated to assess potential cardiovascular safety concerns for aclidinium. OBJE...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rebordosa, Cristina, Plana, Estel, Rubino, Annalisa, Aguado, Jaume, Lei, Alejhandra, Daoud, Sami, Saigi-Morgui, Nuria, Perez-Gutthann, Susana, Rivero-Ferrer, Elena
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8180309/ https://www.ncbi.nlm.nih.gov/pubmed/34103906 http://dx.doi.org/10.2147/COPD.S301624

Ejemplares similares

Characteristics of New Users of Aclidinium Bromide, Aclidinium/Formoterol, and Other COPD Medications in the United Kingdom, Denmark, and Germany
por: Rivero-Ferrer, Elena, et al.
Publicado: (2022)

Risk Assessment of Acute Myocardial Infarction and Stroke Associated with Long-Acting Muscarinic Antagonists, Alone or in Combination, versus Long-Acting beta2-Agonists
por: Rebordosa, Cristina, et al.
Publicado: (2022)

Validation of cardiovascular outcomes and risk factors in the Clinical Practice Research Datalink in the United Kingdom
por: Arana, Alejandro, et al.
Publicado: (2020)

Efficacy of Aclidinium Bromide According to Baseline Therapy: Post-Hoc Analysis of ASCENT-COPD Randomized Trial
por: Wise, Robert A., et al.
Publicado: (2021)

Clinical use of aclidinium in patients with COPD
por: Reid, Debra J, et al.
Publicado: (2014)

The Impact of Exacerbation History on the Safety and Efficacy of Aclidinium in Patients with Chronic Obstructive Pulmonary Disease and Increased Cardiovascular Risk: ASCENT-COPD Trial
por: Wise, Robert A, et al.
Publicado: (2021)

Association between 28 single nucleotide polymorphisms and type 2 diabetes mellitus in the Kazakh population: a case-control study
por: Sikhayeva, Nurgul, et al.
Publicado: (2017)

Aclidinium inhibits human lung fibroblast to myofibroblast transition
por: Milara, Javier, et al.
Publicado: (2011)

New combinations in the treatment of COPD: rationale for aclidinium–formoterol
por: Incorvaia, Cristoforo, et al.
Publicado: (2016)

The Pharmacokinetics, Safety and Tolerability of Aclidinium Bromide 400 μg Administered by Inhalation as Single and Multiple (Twice Daily) Doses in Healthy Chinese Participants
por: Li, Weimin, et al.
Publicado: (2023)

An Evaluation of the Pharmacokinetics, Safety, and Tolerability of Aclidinium/Formoterol Fixed-Dose Combination Administered in Chinese Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease
por: Zhang, Hong, et al.
Publicado: (2022)

Profile of aclidinium bromide in the treatment of chronic obstructive pulmonary disease
por: Sims, Michael W, et al.
Publicado: (2011)

Clinical potential of aclidinium bromide in chronic obstructive pulmonary disease
por: Zhong, Jun, et al.
Publicado: (2014)

Aclidinium Bromide: Clinical Benefit in Patients with Moderate to Severe COPD
por: Suppli Ulrik, Charlotte
Publicado: (2012)

Clinical potential of aclidinium bromide in chronic obstructive pulmonary disease
por: Jones, Paul W
Publicado: (2015)

Patient-reported outcomes and considerations in the management of COPD: focus on aclidinium
por: Lopez-Campos, Jose Luis, et al.
Publicado: (2015)

Effects of aclidinium on determinants of COPD severity: symptoms and quality of life
por: Contoli, Marco, et al.
Publicado: (2016)

Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease
por: Jones, Paul W, et al.
Publicado: (2011)

Cost versus utility of aclidinium bromide 400 µg plus formoterol fumarate dihydrate 12 µg compared to aclidinium bromide 400 µg alone in the management of moderate-to-severe COPD
por: Ramos, Mafalda, et al.
Publicado: (2016)

Aclidinium bromide/formoterol fixed-dose combination therapy for COPD: the evidence to date
por: Moitra, Subhabrata, et al.
Publicado: (2015)

Specific role of combination aclidinium: formoterol in the treatment of chronic obstructive pulmonary disease
por: Matera, Maria Gabriella, et al.
Publicado: (2016)

Effects of Adding Tiotropium or Aclidinium as Triple Therapy Using Impulse Oscillometry in COPD
por: Manoharan, Arvind, et al.
Publicado: (2016)

Reduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium/formoterol
por: Singh, Dave, et al.
Publicado: (2017)

Efficacy and Safety of Aclidinium/Formoterol versus Tiotropium in COPD: Results of an Indirect Treatment Comparison
por: Medic, Goran, et al.
Publicado: (2016)

Is aclidinium alone or combined with a LABA a rational choice for symptomatic COPD patients?
por: Blasi, F., et al.
Publicado: (2017)

ACTIVATE: the effect of aclidinium/formoterol on hyperinflation, exercise capacity, and physical activity in patients with COPD
por: Watz, Henrik, et al.
Publicado: (2017)

Unsystematic NODAL-datalink SINTRAN III information
por: Sveen, O
Publicado: (1975)

Economic evaluation of aclidinium bromide in the management of moderate to severe COPD: an analysis over 5 years
por: Karabis, Andreas, et al.
Publicado: (2014)

Erratum to: Is aclidinium alone or combined with a LABA a rational choice for symptomatic COPD patients?
por: Blasi, F., et al.
Publicado: (2017)

Aclidinium bromide in fixed-dose combination with formoterol fumarate in the management of COPD: an update on the evidence base
por: D’Urzo, Anthony D., et al.
Publicado: (2019)

Risk of Major Cardiovascular and Cerebrovascular Events in Users of Lisdexamfetamine and Other Medications for Attention-Deficit/Hyperactivity Disorder in Denmark and Sweden: A Population-Based Cohort Study
por: Forns, Joan, et al.
Publicado: (2022)

Effect of aclidinium bromide on cough and sputum symptoms in moderate-to-severe COPD in three phase III trials
por: McGarvey, Lorcan, et al.
Publicado: (2016)

Differential Outcomes Following 4 Weeks of Aclidinium/Formoterol in Patients with COPD: A Reanalysis of the ACTIVATE Study
por: Koopman, Maud, et al.
Publicado: (2022)

Cancer Incidence after Initiation of Antimuscarinic Medications for Overactive Bladder in the United Kingdom: Evidence for Protopathic Bias
por: Kaye, James A., et al.
Publicado: (2017)

Patterns of rates of mortality in the Clinical Practice Research Datalink
por: Schmidt, James C. F., et al.
Publicado: (2022)

Symptoms and quality of life in patients with chronic obstructive pulmonary disease treated with aclidinium in a real-life setting
por: Lange, Peter, et al.
Publicado: (2016)

The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorized by symptom status: a pooled analysis
por: Miravitlles, Marc, et al.
Publicado: (2016)

Characteristics of COPD patients initiating treatment with aclidinium or tiotropium in primary care in Catalonia: a population-based study
por: Monteagudo, Mònica, et al.
Publicado: (2017)

Risks of smoking and benefits of smoking cessation on hospitalisations for cardiovascular events and respiratory infection in patients with rheumatoid arthritis: a retrospective cohort study using the Clinical Practice Research Datalink
por: Joseph, Rebecca M, et al.
Publicado: (2017)

1 KM datalink from PS area to computer laboratory
por: Marciano, F, et al.
Publicado: (1964)

Cannot write session to /tmp/vufind_sessions/sess_6ls57dsdrfdtv33ir4ml1qautj